Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Früh

Showing results (511-520 of 552) with videos related to

Pageof 56
Sort By:
Science Translational Medicine|July 19, 2019
A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challengeScott G Hansen, Emily E Marshall, Daniel Malouli, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 25, 2019
Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO expertsPaul Martin Putora, Markus Glatzer, Dirk De Ruysscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
JAMA Oncology|April 26, 2019
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung CancerFiamma Berner, David Bomze, Stefan Diem, et al.
Journal of Neuro-Oncology|June 13, 2025
Practice variations in indication, timing and outcome of Multiple Myeloma patients undergoing surgery for vertebral lesions - results from the European M2Spine study groupVanessa Hubertus, Lennart Viezens, Martin Stangenberg, et al.
Nature|September 13, 2013
Immune clearance of highly pathogenic SIV infectionScott G Hansen, Michael Piatak, Abigail B Ventura, et al.
The Journal of Experimental Medicine|July 20, 2021
PGD2 and CRTH2 counteract Type 2 cytokine-elicited intestinal epithelial responses during helminth infectionOyebola O Oyesola, Michael T Shanahan, Matt Kanke, et al.
Nature Communications|September 30, 2025
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapyDominic Schmid, Bettina Sobottka, Massimiliano Manzo, et al.
Science (New York, N.Y.)|May 25, 2013
Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigmsScott G Hansen, Jonah B Sacha, Colette M Hughes, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
Rhesus Cytomegalovirus-encoded Fcγ-binding glycoproteins facilitate viral evasion from IgG-mediated humoral immunityClaire E Otero, Sophia Petkova, Martin Ebermann, et al.
Pageof 56

Showing results (511-520 of 552) with videos related to

Sort By:
Pageof 56
Science Translational Medicine|July 19, 2019
A live-attenuated RhCMV/SIV vaccine shows long-term efficacy against heterologous SIV challengeScott G Hansen, Emily E Marshall, Daniel Malouli, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 25, 2019
Consolidative thoracic radiotherapy in stage IV small cell lung cancer: Selection of patients amongst European IASLC and ESTRO expertsPaul Martin Putora, Markus Glatzer, Dirk De Ruysscher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 14, 2017
Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH)Solange Peters, Scott Gettinger, Melissa L Johnson, et al.
JAMA Oncology|April 26, 2019
Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung CancerFiamma Berner, David Bomze, Stefan Diem, et al.
Journal of Neuro-Oncology|June 13, 2025
Practice variations in indication, timing and outcome of Multiple Myeloma patients undergoing surgery for vertebral lesions - results from the European M2Spine study groupVanessa Hubertus, Lennart Viezens, Martin Stangenberg, et al.
Nature|September 13, 2013
Immune clearance of highly pathogenic SIV infectionScott G Hansen, Michael Piatak, Abigail B Ventura, et al.
The Journal of Experimental Medicine|July 20, 2021
PGD2 and CRTH2 counteract Type 2 cytokine-elicited intestinal epithelial responses during helminth infectionOyebola O Oyesola, Michael T Shanahan, Matt Kanke, et al.
Nature Communications|September 30, 2025
Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapyDominic Schmid, Bettina Sobottka, Massimiliano Manzo, et al.
Science (New York, N.Y.)|May 25, 2013
Cytomegalovirus vectors violate CD8+ T cell epitope recognition paradigmsScott G Hansen, Jonah B Sacha, Colette M Hughes, et al.
Biorxiv : the Preprint Server for Biology|March 11, 2024
Rhesus Cytomegalovirus-encoded Fcγ-binding glycoproteins facilitate viral evasion from IgG-mediated humoral immunityClaire E Otero, Sophia Petkova, Martin Ebermann, et al.
Pageof 56